Approved HIV Drugs
Approved HIV Drugs
CROI 2010: Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Reduce Response
- Details
- Category: HIV/AIDS
- Published on Tuesday, 02 March 2010 12:57
- Written by Liz Highleyman
Using a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone containing abacavir (Ziagen, also in the Epzicom coformulation) was not associated with poorer response to interferon-based therapy for hepatitis C in HIV/HCV coinfected patients, researchers reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. However, backbones containing zidovudine (AZT; Retrovir) and possibly didanosine (ddI; Videx) were associated with a lower likelihood of achieving a sustained response.
Atripla Label Information Updated to Reflect New Efficacy, Safety, and Resistance Data in Treatment-experienced Patients
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 January 2010 13:15
- Written by FDA
The U.S. Food and Drug Administration (FDA) announced last week that the product label information for the tenofovir/emtricitabine/efavirenz fixed-dose combination pill Atripla will be updated to reflect new clinical trial data regarding efficacy, safety, and development of drug resistance. Overall, post-marketing data continue to show that Atripla remains safe and effective with long-term use.
FDA Grants Traditional Approval for Etravirine (Intelence)
- Details
- Category: HIV Treatment
- Published on Tuesday, 01 December 2009 13:13
- Written by Tibotec
On November 24, the U.S. Food And Drug Administration (FDA) granted traditional approval of Tibotec's next-generation non-nucleoside reverse transcriptase inhibitor etravirine (Intelence), based on longer-term data from 2 pivotal trials showing that the drug was safe and effective over 48 weeks in treatment-experienced HIV patients with resistant virus.
Antiretroviral Therapy Reduces Overall Mortality, but Effects Differ According to HIV Risk Group
- Details
- Category: HIV Treatment
- Published on Friday, 08 January 2010 13:15
- Written by Liz Highleyman
Effective combination antiretroviral therapy (ART) has dramatically reduced overall mortality among people with HIV, according to data from the large HIV-CAUSAL Collaboration published in the January 2, 2010 issue of AIDS. Overall, starting treatment reduced the risk of death by about half. Those who started with a low CD4 cell count saw the largest reduction in mortality, but even those who started with more than 500 cells/mm3 had improved survival. However, the HIV-CAUSAL study and another study in Brazil both found that people who became infected with HIV via injection drug use did not benefit as much those infected through sex.
Meta-Analysis of Truvada vs Epzicom Backbones Used with Boosted Protease Inhibitors for First-line Antiretroviral Therapy
- Details
- Category: HIV Treatment
- Published on Friday, 09 October 2009 14:13
- Written by HIVandHepatitis.com
First-line antiretroviral therapy (ART) that includes a nucleoside/nucleotide backbone of tenofovir/emtricitabine (the drugs in the Truvada coformulation) was more effective than regimens containing abacavir/lamivudine (the drugs in the Epzicom coformulation) for HIV patients with high pre-treatment viral load, according to a meta-analysis published in the October 2009 issue of HIV Medicine.
More Articles...
- STARTMRK Trial Shows Raltegravir (Isentress) Works as Well as Efavirenz (Sustiva) in Treatment-naive HIV Patients
- GlaxoSmithKline Meta-analysis Does Not Show Elevated Cardiovascular Risk Associated with Use of Abacavir
- CROI 2009: Cancer Incidence in Clinical Trials of Raltegravir (Isentress)
- CROI 2009: Large Meta-analysis Indicates Antiretroviral Therapy Works as Well for Women as for Men
Web Design and Development by